<DOC>
	<DOCNO>NCT00145145</DOCNO>
	<brief_summary>The purpose study determine whether immunization MAGE-3.A1 peptide mix CpG 7909 result detectable immune response ; determine safety vaccine ; document tumor response vaccine .</brief_summary>
	<brief_title>Immunization With MAGE-3.A1 Peptide Mixed With Adjuvant CpG 7909 Patients With Metastatic Melanoma</brief_title>
	<detailed_description>Patients vaccinate every two week six occasion . On vaccination day , MAGE-3.A1 peptide ( 300 µg ) mix CpG 7909 ( 5 mg ) administer twice intradermally ( 10 % dose ) twice subcutaneously ( 40 % dose ) arm thighs . Tumor stag perform inclusion week 13 . PBL collection perform start treatment , week 3 , 7 13 . They provide T lymphocytes immunological analysis . Additional cycle immunization propose patient without tumor progression require another treatment . A second cycle 3 injection 6-week interval start week 17 vaccine , follow third cycle 12 injection 3-month interval start month 11 . At time , progression disease necessitate treatment allow study , result study withdrawal .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Histologically proven cutaneous melanoma , clear cell sarcoma , consider subtype melanoma . 2 . Melanoma must one follow AJCC 2002 stage : Regional metastatic disease ( T ; N2b , N2c N3 ; M0 ) . Distant metastatic disease ( T ; N ; M1a , M1b M1c ) , except brain leptomeningeal localization , except elevate LDH . 3 . Patients must HLAA1 . 4 . Melanoma must express MAGE3 gene , determine RTPCR . 5 . Presence least one measurable nonmeasurable tumor lesion , exclude leptomeningeal metastasis ( see Section 7.3 ) . 6 . Expected survival least 3 month . 7 . Karnofsky performance scale ≥70 WHO performance status 0 1 . 8 . Within last 4 week prior study day 1 , vital laboratory parameter within normal range , except follow laboratory parameter , must within range specify : Lab Parameter Range Hemoglobin ≥ 10 g/dl ≥ 6,25 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Serum creatinin ≤ 2.0 mg/dl ≤ 177 mmol/l Serum bilirubin ≤ 2.0 mg/dl ≤ 34.2 mmol/l ASAT ALAT ≤ 2 x normal upper limit LDH ≤ normal upper limit . 9 . Viral test : HIV ( human immunodeficiency virus ) : negative antibody . HBV ( hepatitis B virus ) : negative antigen ; antibody may positive . HCV ( hepatitis C virus ) : negative antibody . 10 . Age ≥ 18 year 11 . Able willing give valid write informed consent . 1 . Previous treatment one regimen systemic chemotherapy , combine nonspecific immunotherapy interferon alpha interleukin . Chemoimmunotherapy radiotherapy must stop within precede 4 week ( 6 week nitrosoureas mitomycin C ) . 2 . Previous treatment vaccine know likely contain MAGE3.A1 antigen , unless evidence CTL response antigen induce vaccine . 3 . Clinically significant heart disease ( NYHA Class III IV ) i.e . NYHA class 3 congestive heart failure ; myocardial infarction within past six month ; unstable angina ; coronary angioplasty within past 6 month ; uncontrolled atrial ventricular cardiac arrhythmia ) . 4 . Active immunodeficiency autoimmune disease . Vitiligo exclusion criterion . 5 . Other serious acute chronic illness , e.g . active infection require antibiotic , bleed disorder , condition require concurrent medication allow study . 6 . Other malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ . 7 . Lack availability immunological clinical followup assessment . 8 . Participation clinical trial involve another investigational agent within 4 week prior enrollment . 9 . Pregnancy breastfeed . 10 . Women childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Peptide</keyword>
	<keyword>MAGE</keyword>
	<keyword>CpG</keyword>
</DOC>